HC Wainwright Equities Analysts Increase Earnings Estimates for Addex Therapeutics Ltd (NASDAQ:ADXN)

Addex Therapeutics Ltd (NASDAQ:ADXN) – Equities researchers at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Addex Therapeutics in a report released on Wednesday, October 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.49 per share for the year, up from their prior estimate of ($0.36). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Addex Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Addex Therapeutics’ Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.00 EPS and FY2025 earnings at ($0.28) EPS.

Addex Therapeutics Trading Up 0.4 %

Shares of ADXN stock opened at $9.44 on Friday. The stock has a market cap of $10.01 million, a P/E ratio of -0.55 and a beta of 1.79. Addex Therapeutics has a 1 year low of $5.00 and a 1 year high of $27.90. The stock has a 50 day simple moving average of $9.17 and a 200 day simple moving average of $10.57.

Addex Therapeutics (NASDAQ:ADXN) last posted its quarterly earnings results on Monday, September 30th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70). Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.26 million.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.